Microbix Achieves Further QAPs Sales Record

Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency

MISSISSAUGA, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over one million Canadian Dollars (“C$ 1 Million”) of its quality assessment products (“QAPs”) to a leading agency that provides clinical laboratory accreditation services. This is Microbix’s largest-ever individual shipment to a lab proficiency-testing (“PT”) and external quality assessment (“EQA”) services provider.

The orders were for Microbix QAPs, in both the traditional liquid-vials and formatted onto Copan FLOQSwabs, to support proficiency programs covering numerous infectious diseases across multiple disease categories. The QAPs provided included those to support antigen and molecular (i.e., PCR) tests. They will be used to help validate accuracy of testing on a wide range of test systems – ranging from high-throughput automated instruments to lower volume point-of-care and lab-developed tests.

These sales were realized in the fourth quarter of calendar 2023 (i.e., Q1 of Microbix’s fiscal 2024). As with the over C$ 1 Million set of QAPs purchase orders (“P.Os.”) from a multinational test-maker announced in late September, this PT/EQA-oriented set of P.Os. was nearly equivalent to a full year’s worth of QAPs sales from 2020 and is indicative of Microbix beginning to realize its targeted sales growth for this segment of its business. The unit number of QAPs shipped under this set of P.Os. is in the tens of thousands and Microbix expects ongoing sales to this longtime PT/EQA customer.

Microbix believes this record set of orders substantiates its technical leadership in creating and producing test controls (i.e., QAPs). Specifically, that the accuracy and reliability of sophisticated clinical laboratory testing must be validated by PT/EQA programs and that such programs must be supported by cross-platform compatible QAPs in formats that represent actual patient samples (i.e., both liquids & swabs).

Cameron Groome, CEO & President of Microbix, stated, “We’re delighted to advance our relationship with this international leader in the PT/EQA sector of the clinical laboratory industry. We understand that we earned this increased level of business due to the technical superiority of Microbix QAPs – namely their providing clinically-relevant pathogen-signals and whole-process validation while being entirely compatible with each of the instrument and assay systems now in use within laboratories.”